AM I NEXT? NO LOVE AT GLAXOSMITHKLINE (07/22/25)

Am I Next? Layoffs at GSK - GlaxoSmithKline.

JULY 22, 2025 — 150 EMPLOYEES IN CAMBRIDGE, MASSACHUSETTS

The company has announced the cessation of manufacturing operations at a Cambridge facility.

The work stoppage will impact 150 employees at its Cambridge, Massachusetts facility.The layoffs will occur between October 4, 2025, and March 31, 2025.

According to a spokesperson, “One of the company’s three locations in Cambridge would transition to only research and development work, with manufacturing moving to Marietta, Pennsylvania. The Binney Street site remains a vital facility in our R&D network, contributing to our presence in the greater Boston area. We’re always focused on allocating resources to our priorities and making sure we have the right people in the right teams. These actions fit into that strategy.”

AUGUST 7, 2021 — GSK CLOSING CARLISLE, PENNSYLVANIA PLANT WITH 308 LAYOFFS. PRODUCTION OUTSOURCED TO PUERTO RICO.

The company has confirmed that it will close a manufacturing facility in Carlisle, Pennsylvania with the production of Emergen-C, a powdered drink mix vitamin C supplement, ending by mid-year 2021. 308 employees will be impacted by the closure.

According to a company statement, “After careful review, GSK has decided to close the Carlisle, PA site to consolidate volumes and generate efficiencies by moving the site’s production to our Guayama, Puerto Rico facility. Based on this decision, which impacts approximately 308 employees, production will be phased out of Carlisle by mid-2021, with a full exit by April 2022.

Reminder: Many management decisions may be driven by activist investor Elliott Management.

Update: 9/11/21 — changed employee count and full exit date.

JULY 7, 2021 — GSK CLOSING MEMPHIS, TENNESSEE PLANT

The company has announced that it will be closing its facility on President’s Island by September 2022, and laying off all 156 current workers. Layoffs began in June 2021.

Under extreme pressure from activist investor Elliott Management, GSK is planning to split in two and plans to spin off its consumer products group to concentrate on vaccines and pharmaceuticals. The facility produces Polident denture cleaning products and other oral care brands.

APRIL 22, 2019 — GSK LAYOFFS IN PENNSYLVANIA

GSK announced that it will lay off about 100 employees at its research and development center in Upper Providence, Pennsylvania as part of a reorganization that will refocus the company’s research on genetics, the immune system, and oncology.

A GSK spokesperson offered, “The future direction of our portfolio has become clearer, prioritizing innovation and moving toward delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK’s R&D operations to grow overall with increased investment.”

OCTOBER 18, 2018 — GSK SHEDS 100 EMPLOYEES IN MEMPHIS, TENNESSEE FACILITY

GSK Consumer Health-Global Manufacturing & Supply, a division of GlaxoSmithKline, will be permanently laying off approximately 100 jobs at their President’s Island facility in Memphis, Tennessee. The decision was driven by the end of a contract manufacturing agreement.

SEPTEMBER 19, 2018 — Original post…

Brentford, London-based pharmaceutical giant GlaxoSmithKline has announced that it would be implementing is previously-announced restructuring plan and laying off 650 employees in the United States; including 450 national field sales representatives and 100 “back office” employees in both their Philadelphia, Pennsylvania, and Research Triangle Park, North Carolina offices.

In its July 2018 Second Quarter earnings release, the company noted that “Focused improvements in operating performance have helped deliver increases in earnings and cash flow.” Chief Executive Emma Walmsley also announced “a new major restructuring program, which aims to significantly improve the competitiveness and efficiency of the Group’s cost base with savings delivered primarily through supply chain optimization and reductions in administrative costs.”

For those who are following the pharmaceutical industry in the trade press, the restructuring and layoffs should come as no surprise. Especially with the increased use of consumer-direct advertising through radio, television, and targeted social media outlets and the reduction in drug “detail” sales representatives calling on physicians. Drugs coming off-patent, the rise of generic bio-similar products, and the pricing pressures of large drug purchasing intermediaries are also weighing heavily on the industry.

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

NO LOVE AT SANOFI (04/14/24)

Am I Next? French Drug Manufacturer Sanofi to layoff 400 people.

APRIL 14, 2024 — 100 SOUTH SAN FRANCISCO EMPLOYEES TARGETED

Sanofi is planning to shut down its former acquisition, Amunix Pharmaceuticals, located in South San Francisco, California, and lay off its 100 employees between early June through mid-September 2024.

According to a company spokesperson, "This new step involves making strong decisions for the future of our company.”

JULY 24, 2022 — 400 LAYOFFS IN SALES TEAMS

The company has announced that it will be laying off 400 employees from its diabetes and cardiovascular sales team.

According to a company spokesperson, “The reorganization will enable us to continue to adapt to the ever-changing market, and allow us to focus on our recent launches while setting us up for success in the future."

SEPTEMBER 15, 2021 — 38 SAN FRANCISCO LAYOFFS

Sanofi has announced the wind-down of Principia Biopharma’s San Francisco, California laboratories and lay off 38 employees on October 8, 2021.  The facility will be the site will be permanently vacated by April 2022.

According to a company spokesperson, “This was a difficult decision, and we plan to undertake this process responsibly and assist our employees with this transition.”

JULY 18, 2019 — STEALTH LAYOFFS?

It appears that the company is reducing its U.S. headcount — with hundreds of jobs at risk.

Preparatory to layoffs, the company is executing its VEEP strategy.

According to a company spokesperson, “Sanofi US offered a Voluntary Early Exit Program (VEEP) for eligible employees across our organization. We are not disclosing the number of employees who accepted VEEP. As we’ve discussed on our earnings calls, Sanofi has returned to growth and with that, we are continuing to focus on strategically aligning our operations and expenses to be able to invest in key R&D programs that will deliver important new medicines for patients.”

FEBRUARY 9, 2018 — Original Post…

Sanofi, based in France and one of the world's largest multinational pharmaceutical companies in the world, has announced a new round of layoffs in its continuing restructuring program to meet competitive pressures.

Published reports indicate that the new round of workforce adjustments will result in at least 400 layoffs in their United States sales force, mostly involved with Sanofi’s diabetes and cardiovascular products.

It is no secret that drug-makers are being subject to expiring protections on lucrative proprietary drugs, bio-similar compounds, and competitive purchasing pressures from distributors who are kicking back incentives to large institutions. In addition, most drug manufacturers are reducing their direct-to-physician contracts in favor of advertising using both mainstream media and internet channels aimed at a targeted audience.

Of course, the company was quick to employ corporate-speak, using spokesperson  Ashleigh Koss to explain that the reduction in force will "enable us to continue to adapt to the ever-changing market, and allow us to focus on our recent launches while setting us up for success in the future.” She could have easily added, “move along, nothing new to see here folks.”

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT MERCK (08/01/25)

Am I Next? Merck & Company layoffs

AUGUST 1, 2025 — 6,000 EMPLOYEES TARGETED

The company has announced a $3 billion, multi-year cost-saving plan that will result in an 8% reduction in its global workforce.

The reduction initiative will impact 6,000 employees in administrative, sales, and research-and-development roles.

CEO Robert Davis noted, The restructuring program at Merck will help to redirect investment and resources from more mature areas of our business to our burgeoning array of new growth drivers. The company will continue to optimize its manufacturing network by aligning the geography of its global operations with its customers, consistently evaluating its manufacturing to ensure medicines and vaccines are produced and distributed close to the communities and patients it serves."

MARCH 23, 2025 — 163 PENNSYLVANIA EMPLOYEES

Merck announced that 163 employees were being laid off in three phases at the company’s Riverside, Pennsylvania, Cherokee manufacturing facility.

According to a company statement, “Merck remains committed to Pennsylvania and employs approximately 14,000 people in the state. The company has invested over $3 billion to date in our Pennsylvania operations manufacturing medicines and vaccines that help save and improve lives around the world.”

JANUARY 23, 2023 — 133 LAYOFFS

Merck announced that 133 employees were being laid off at the company’s Billerica, Massachusetts, research and development facility.

According to a company spokesperson, “We will keep our strong research unit footprints for neuroscience and immunology and oncology, focusing on selected biological areas and scientific capabilities. The cuts represent a 26% reduction to the Billerica staff, which has roughly 500 employees.”  

JULY 10, 2022 — 500 LAYOFFS NATIONWIDE

The company is engaged in a cost-cutting initiative to free-up capital for more innovative projects. A company spokesperson commented, “Merck is eliminating 500 positions nationwide in select sales and headquarters commercial teams, effective January 3, 2023.

MARCH 29, 2022 — 170 ACCELERON LAYOFFS

After completing its November 2022, acquisition of Cambridge, Massachusetts-based Acceleron Pharma, the company has announced that it will be laying off 170 former Acceleron employees scheduled between May 31, 2022 – November 18, 2022.

According to a company spokesperson, "These actions are in alignment with our overall strategy of integrating the two companies. Currently, there are no further plans for company-wide restructuring or layoffs."

OCTOBER 17, 2019 UPDATE — MASS LAYOFF IN HUMAN HEALTH DIVISION’S SALES DEPARTMENT

The company has announced that it will be laying off 500 employees, mostly field sales representatives and administrative people in the Human Health Division based in Lansdale and North Wales, Pennsylvania in what the company characterizes as a permanent “reduction in force” commencing on January 3, 2020. This includes employees outside of the Pennsylvania field headquarters.

OCTOBER 23, 2017 — Previous post…

It appears that Kenilworth, New Jersey-based Merck & Company will be following other pharmaceutical companies such as Eli Lilly (3,500 layoffs) and Teva (7,000 layoffs)  in reorganizing and realigning their core functionality and personnel. Merck will reduce their labor force by approximately 1,800 workers, primarily in sales and who serve as drug detail representatives to primary-care doctors, endocrinologists, and hospitals. 

Gone are the days of exclusive-to-physician marketing and the past practice of attempting to influence individual prescribers with samples and brand reminders such as golf balls and other tchotchkes. Or allowing the high-prescribers to fulfill their CEU (Continuing Education Credits) at high-end resorts. Not to mention paying “honoraria” for sponsored speaking events. Now, with the advent of the internet and interactive media, we can see more targeted marketing of so-called associative ads. Drugs are marketed directly to consumers with the benefit of the constant repetition of the horrendous potential side effects dulling the perception of prescription dangers. It is not uncommon for patients to research their conditions and symptoms on the internet and request (or demand) certain therapies or branded drugs from their attending physicians.

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?